Starling Oncology (STLNW) Gross Margin (2021 - 2026)
Starling Oncology's (STLNW) quarterly Gross Margin came in at 16.84% in Q2 2026, up 223.0% on a YoY basis from 5.21% in Q2 2025, and up 6.51% quarter-over-quarter from 15.81% in Q1 2026.
Powered by 
Analysis
Starling Oncology (STLNW) Gross Margin (2021 - 2026) Analysis & Trends
Starling Oncology (STLNW) has reported Gross Margin for 6 consecutive years, with 16.84% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gross Margin rose 223.0% year-over-year to 16.84%; the trailing twelve-month figure through Jun 2026 stood at 50.73% (down 24.0% YoY), and the FY2025 full-year result was 56.13%, up 363.0% from the prior year.
- Gross Margin improved to 16.84% in Q2 2026 per STLNW's latest filing, from 15.81% in the prior quarter.
- Across five years, Gross Margin topped out at 166.73% in Q4 2024 and bottomed at 13.85% in Q3 2025.
- Historically, Gross Margin has averaged 49.11% across 5 years, with a median of 44.23% in 2022.
- The sharpest annual moves came in 2024 and 2025: Gross Margin jumped 12310 bps in 2024, then plunged 3820 bps in 2025.
- Over 5 years, Gross Margin stood at 46.26% in 2022, then declined by 6 bps to 43.62% in 2023, then soared by 282 bps to 166.73% in 2024, then slipped by 3 bps to 160.96% in 2025, then tumbled by 90 bps to 16.84% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 16.84%, 15.81%, and 160.96% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Davita | 11.89 Bn | 11.20 Bn | 1.16 Bn | 32.70% |
| 2 | RadNet | 5.51 Bn | 4.78 Bn | 88.08 Mn | 14.14% |
| 3 | Fresenius Medical Care AG | 4.79 Bn | 4.09 Bn | 1.52 Bn | 26.95% |
| 4 | Concentra Group Holdings Parent | 4.28 Bn | 4.12 Bn | 192.10 Mn | 31.70% |
| 5 | Privia Health | 2.57 Bn | 2.16 Bn | - | - |
| 6 | Pediatrix Medical | 2.14 Bn | 1.74 Bn | - | - |
| 7 | Progyny | 2.11 Bn | 1.87 Bn | 89.30 Mn | 25.48% |
| 8 | Surgery Partners | 1.85 Bn | 1.63 Bn | 622.10 Mn | 73.28% |
| 9 | U S Physical Therapy | 1.18 Bn | 1.15 Bn | 41.94 Mn | 19.59% |
| 10 | Starling Oncology | 4.13 Mn | -36.96 Mn | 27.17 Mn | 16.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.84% |
| Mar 31, 2026 | 15.81% |
| Dec 31, 2025 | 160.96% |
| Sep 30, 2025 | 13.85% |
| Jun 30, 2025 | 14.61% |
| Mar 31, 2025 | 16.52% |
| Dec 31, 2024 | 166.73% |
| Sep 30, 2024 | 14.38% |
| Jun 30, 2024 | 52.81% |
| Mar 31, 2024 | 47.71% |
| Dec 31, 2023 | 43.62% |
| Sep 30, 2023 | 45.19% |
| Jun 30, 2023 | 44.06% |
| Mar 31, 2023 | 43.81% |
| Dec 31, 2022 | 46.26% |
| Sep 30, 2022 | 44.40% |
| Jun 30, 2022 | 46.04% |
| Mar 31, 2022 | 50.37% |
| Dec 31, 2021 | 47.71% |
| Sep 30, 2021 | 51.43% |